James Evans is an Oncology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1024 1st St N
Alabaster, AL 350078703
Telephone
205-664-4051Registry record last updated 18 Oct 2016.
Clinical trials
- Acceptability and Tolerance Study of a Plant-based Tube Feed
Sponsor: Société des Produits Nestlé (SPN)
- Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
- NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing
Sponsor: University of North Carolina, Chapel Hill
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
66 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202510 payments
- PFIZER INC.Program year202513 payments
- Daiichi Sankyo Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.2%Kinase inhibitor9.5%Brukinsa22%Ibrance17%Calquence13%Imbruvica11%Jakafi10%Kisqali9%Imatinib Mesylate9%Koselugo5%Stivarga5%Part D<11 patientsAromatase Inhibitor9.2%Letrozole71%Anastrozole22%Exemestane8%Part D<11 patients+ 8 more classes in this area
Nervous system
31%Opioid Agonist14.8%Oxycodone-Acetaminophen36%Oxycodone Hcl25%Morphine Sulfate Er18%Tramadol Hcl10%Fentanyl7%Hydromorphone Hcl4%Part D<11 patientsGabapentinoids4.6%Gabapentin88%Pregabalin12%Part D<11 patients+ 7 more classes in this area
Respiratory
10.9%Opioid Agonist10%Hydrocodone-Acetaminophen100%Part D≥69 patientsPhenothiazine0.9%Promethazine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”